TissueChips

Dr. James J. Hickman elected as Fellow of the National Acadamy of Inventors!

by
fellow

Dr. James J. Hickman elected as Fellow of the National Acadamy of Inventors Hesperos is excited to announce that Chief Scientist, Dr. James J. Hickman, has been elected fellow of the National Academy of Inventors (NAI).  This year’s class included 175 innovators from around the world – all of which will be inducted and honored … Read more

Dr. Hickman Presents Human-on-a-Chip® at Florida Simulation Summit 2020

by
human-on-a-chip

Presentation Highlights

This is a company overview presentation given by Dr. James Hickman at this years Florida Simulation Summit 2020 in October.  Learn more about the technology and exciting path ahead. Key highlights from the presentation include:

  • A brief history of Hesperos
  • How the Human-on-a-Chip technology works and the current state of the technology
  • Key applications and path forward

Human-on-a-Chip®

Functional in vitro models that accurately predict how new drug candidates will impact the human body – something that has previously required animal testing or human clinical trials to determine.

What’s on each Chip?

Systemic toxicology models with interlinked organs, including: heart, liver, lung, brain, skin, muscle, GI tract, kidney, pancreas, endocrine, bone marrow and the neuromuscular junction in a serum free, recirculating medium utilizing a pumpless platform.

Hesperos listed among 2021 Top Tech Startups in Orlando

by
hesperos

The Tech Tribune, the journalistic arm of Crunchbase, recently selected Hesperos as one of the top 10 technology startups in Orlando. We are proud to be listed among the best companies in the City Beautiful. Award recipients cover a wide range of industries and were selected based on several factors including revenue potential and leadership … Read more

Unraveling the Pathologic Role of Skeletal Muscle in ALS

by
ALS

Unraveling the pathologic role of skeletal muscle in ALS A key challenge in developing effective therapies for amyotrophic lateral sclerosis has been a poor understanding of the disease pathology. To address this issue, a team of scientists from University of Central Florida and Hesperos have created a new ALS skeletal muscle Human-on-a-Chip® model which could … Read more

ALS pathology investigated by UCF/Hesperos Researchers Utilizing a Human-on-a-Chip® model

by
als

UCF/HESPEROS RESEARCHERS UTILIZE HUMAN-ON-A-CHIP® APPROACH TO MODEL ALS PATHOLOGY Key Findings Data supports use of functional neuromuscular junction (NMJ) system to evaluate amyotrophic lateral sclerosis pathology  First study to validate the use of Deanna protocol in a human system as a strategy for treating ALS  Press Release  ORLANDO, Fla. — The Hybrid Systems Lab at … Read more

Hesperos demonstrates innovative Human-on-a-Chip® approach to modeling innate immune system response following tissue damage and acute inflammation

by
hesperos

— New publication in Advanced Science validates potential use in evaluating certain immune responses in drug discovery and systemic diseases, including Coronavirus Disease 2019 (COVID-19)— — Hesperos’ immune system-on-a-chip features recirculating immune cells with the key organ mimics heart, skeletal muscle and liver ORLANDO, Fla. – June 2, 2020 — Hesperos Inc., pioneers of the … Read more

Preclinical Stages of Alzheimer’s Disease and Mild Cognitive Impairment modeled with HUMAN-ON-A-CHIP®

by
Hesperos

PRECLINICAL STAGES OF ALZHEIMER’S DISEASE AND MILD COGNITIVE IMPAIRMENT MODELED WITH HESPEROS HUMAN-ON-A-CHIP® SYSTEM — Peer-reviewed publication in Alzheimer’s & Dementia: Translational Research & Clinical Interventions validates potential of drug discovery platform and ability to study early stages of disease pathology — ORLANDO, Fla. – May 28, 2020 – Hesperos Inc., pioneers of the Human-on-a-Chip® … Read more

Human-on-a-chip for Rare Diseases discussion

by
Human-on-a-Chip

HUMAN-ON-A-CHIP FOR RARE DISEASES DISCUSSION In our latest publication, UCF & Hesperos researchers discuss how Human-on-a-chip systems can be used to address the unique challenges facing rare diseases. Researchers cite that rare diseases are “limited by the high cost of research and low target population.” Further Discussion of Human-on-a-chip® technology Researchers further discuss how “Human-on-a-chip … Read more